Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Monte Rosa Therapeutics (GLUE) Accumulated Depreciation & Amortization (2023 - 2025)

Monte Rosa Therapeutics' Accumulated Depreciation & Amortization history spans 3 years, with the latest figure at $27.6 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 35.6% year-over-year to $27.6 million; the TTM value through Dec 2025 reached $27.6 million, up 35.6%, while the annual FY2025 figure was $27.6 million, 35.6% up from the prior year.
  • Accumulated Depreciation & Amortization reached $27.6 million in Q4 2025 per GLUE's latest filing, up from $25.5 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $27.6 million in Q4 2025 to a low of $8.6 million in Q2 2023.
  • Average Accumulated Depreciation & Amortization over 3 years is $17.5 million, with a median of $17.3 million recorded in 2024.
  • The largest YoY upside for Accumulated Depreciation & Amortization was 89.16% in 2024 against a maximum downside of 15.49% in 2024.
  • A 3-year view of Accumulated Depreciation & Amortization shows it stood at $12.2 million in 2023, then soared by 66.32% to $20.4 million in 2024, then skyrocketed by 35.6% to $27.6 million in 2025.
  • Per Business Quant, the three most recent readings for GLUE's Accumulated Depreciation & Amortization are $27.6 million (Q4 2025), $25.5 million (Q3 2025), and $23.4 million (Q2 2025).